Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
HU 308 is a potent and selective CB2 receptor agonist (Ki values are 22.7 nM and > 10 μM for CB2 and CB1 receptors respectively, EC50 = 5.57 nM). Displays antiallodynic activity in the rat hindpaw incision model of postoperative pain. Also neuroprotective and improves motor performance in a mouse model of Huntington's Disease.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 414.62. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.41 mL||12.06 mL||24.12 mL|
|5 mM||0.48 mL||2.41 mL||4.82 mL|
|10 mM||0.24 mL||1.21 mL||2.41 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References are publications that support the biological activity of the product.
LaBuda et al (2005) Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur.J.Pharmacol. 527 172 PMID: 16316653
Hanus et al (1999) HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc.Natl.Acad.Sci.USA 96 14228 PMID: 10588688
Palazuelos et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132 3152 PMID: 19805493
If you know of a relevant reference for HU 308, please let us know.
Keywords: HU 308, HU 308 supplier, Potent, selective, CB2, agonists, cannabinoids, Receptors, HU308, cb2r, huntingtons, disease, 3088, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for HU 308 include:
Acevedo-Canabal et al (2019) Altered Swimming Behaviors in Zebrafish Larvae Lacking Cannabinoid Receptor 2. Cannabis Cannabinoid Res 4 88 PMID: 31236475
Presley et al (2015) Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Brain Res 3 e00159 PMID: 26196013
Sheng et al (2019) Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain. Pain Res Manag 2019 1260353 PMID: 31354896
Ke et al (2016) Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages PLoS One 11 e0155076 PMID: 27611972
Gianella-Borradori et al (2015) Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Bioorg Med Chem 23 241 PMID: 25487422
Sardinha et al (2014) Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Pharmacol Res Perspect 2014 978678 PMID: 24803745
Solbrig et al (2013) Prospects for cannabinoid therapies in viral encephalitis. Proc Natl Acad Sci U S A 1537 273 PMID: 24021420
Do you know of a great paper that uses HU 308 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review HU 308 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.